Autopsy report · NCT01312844
A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
Cause of deathStaffing, sites or logistics
“This was an inpatient study, but PI left inpatient service at MGH”
Life of this trial
- Ran for about 2 years 3 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 4 years 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- University, hospital or other
- Conditions
- Depression
- Interventions
- Scopolamine
- Participants
- 7
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
“PI left Massachusetts General Hospital Inpatient service” - Over Active Bladder Instillation Study - Botox
“Study terminated early due to PI's extended medical leave.” - Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
“Drug expired and access to additional supply ended. PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.” - Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
“PI closed study early, all patients experienced severe toxicities and progressed” - Aliskiren and Renin Inhibition in Diastolic Heart Failure
“Difficulty in recruiting patients and then the PI left the institution”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.